Therapeutic peptides for demyelinating conditions

Details Therapeutic peptides for demyelinating conditions Therapeutic peptides for demyelinating conditions

2005-06-10

2008-11-25

Bunner, Bridget E (Department: 1647)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

15 to 23 amino acid residues in defined sequence

C530S300000, C435S810000, C435S975000, C514S013800, C514S014800

Reexamination Certificate

active

07456252

ABSTRACT:
The invention provides peptide compositions and methods of making and using therapeutic compositions comprising peptides for the treatment of a subject having a demyelinating condition.

REFERENCES:
patent: 5614192 (1997-03-01), Vandenbark
patent: 5827516 (1998-10-01), Urban et al.
patent: 5880103 (1999-03-01), Urban et al.
patent: 6509033 (2003-01-01), Urban et al.
patent: 2003/0103993 (2003-06-01), Deshpande et al.
patent: 2004/0038887 (2004-02-01), Strominger et al.
patent: WO 94/04171 (1994-03-01), None
patent: WO 02/057291 (2002-07-01), None
Wells. J.A. Additivity of mutational effects in proteins. Biochemistry 29 (37): 8509-8517, 1990.
Ngo et al. Computational complexity, protein structure prediction, and the Levinthal paradox. The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495, 1994.
Fridkis-Hareli et al. Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis. J Clin Invest 109(12): 1635-1643, 2002.
Stern et al. Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 102(5): 1620-1625, 2005.
Fridkis-Hareli et al. Binding of random copolymers of three amino acids to class II MHC molecules. Int Immunol. 11(5):635-641, 1999.
Fridkis-Hareli et al. 2001 Synthetic peptides that inhibit binding of the myelin basic protein 85-99 epitope to multiple sclerosis-associated HLA-DR2 molecules and MBP-specific T-cell responses. Hum Immunol 62(8): 753-763, 2001.
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotech 18(1): 34-39, 2000.
Bork, A. Powers and pitfalls in sequence analysis: the 70% hurdle. Genome Res 10: 398-400, 2000.
Doerks et al. Protein annotation: detective work for function prediction. Trends in Genetics 14(6): 248-250, 1998.
Smith et al. The challenges of genome sequence annotation or “The devil is in the details”. Nature Biotech 15: 1222-1223, 1997.
Brenner, S.E. Errors in genome function. Trends in Genetics 15(4): 132-133, 1999.
Bork et al. Go hunting in sequence databases but watch out for the traps. Trends in Genetics. 12(10): 425-427, 1996.

Affiliated with

Also associated with

Rating

Therapeutic peptides for demyelinating conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic peptides for demyelinating conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic peptides for demyelinating conditions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4029858